



VRL/SEC/EXCHANGE

Dept. of Corporate Services
The Stock Exchange, Mumbai
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai

18.11.2016



Sub: Submission of Unaudited Financial results as on 30.09.2016

Dear Sir/Madam,

Please find enclosed herewith copy of Unaudited Financial Results (provisional), Statement of assets and liability along with limited review report for the quarter ended on 30.09.2016 which were taken on record by the Board of Directors at its meeting held on 09.11.2016.

Further, we wish to inform you that we have already submitted the results through XBRL filing on 09.11.2016 within the stipulated time after conclusion of Board Meeting.

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED.

(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com
www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PI C000705

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 30TH SEPTEMBER, 2016**

(Rs. In Millions)

S. No.	PARTICULARS	Quarter Ended on			Half Year Ended on		Year Ended on
		30/09/2016 Unaudited	30/06/2016 Unaudited	30/09/2015 Unaudited	30/09/2016 Unaudited	30/09/2015 Unaudited	31/03/2016 Audited
1	Net Sales/ Income from operations						
	(a) Net Sales (Net of Excise Duty)	1060.13	1015.15	1008.66	2075.28	1993.85	3969.84
	(b) Other Operating Income	11.04	18.3	50.78	27.34	54.71	57.11
	Total Income from Operation (Net)	1,071.17	1,031.45	1,059.44	2,102.62	2,048.56	4,026.95
2	Expenses						
	(a) Consumption of raw materials	670.52	632.17	654.64	1332.69	1244.65	2,419.98
	(b) (Increase)/ Decrease in stock in trade	(0.03)	(18.19)	(7.58)	(18.22)	(2.03)	(21.66)
	(c) Employee benefits expense	62.31	59.43	61.51	121.74	123.33	250.24
	(d) Depreciation & amortisation expense	99.79	38.79	101.05	198.58	200.66	404.68
	(e) Other expenses	145.53	149.10	147.58	294.63	287.38	582.84
	Total expense	978.12	951.30	957.21	1,929.42	1,853.99	3,636.08
3	Profit from operations before other income, finance costs and exceptional items (1-2)	93.05	80.15	102.23	173.20	194.57	390.87
	EBIDTA (3+2(D)	192.8	178.94	203.3	371.8	395.2	795.55
4	Other income	1.50	1.24	1.19	2.74	2.23	6.65
5	Profit before finance costs and exceptional items (3+4)	94.55	81.39	103.42	175.94	196.80	397.52
6	Finance Costs	83.14	69.55	87.37	152.69	178.82	367.40
7	Profit after finance costs but before exceptional items (5-6)	11.41	11.84	16.05	23.25	17.98	30.12
8	Exceptional items	-	-	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	11.41	11.84	16.05	23.25	17.98	30.12
10	Tax Expenses	-	-	-	-	-	18.08
11	Profit from ordinary activities after tax (9-10)	11.41	11.84	16.05	23.25	17.98	12.04
12	Exceptional items	-	-	-	-	-	-
13	Net profit for the period (11-12)	11.41	11.84	16.05	23.25	17.98	12.04
14	Paid up Equity Share Capital	114.42	114.42	114.42	114.42	114.42	114.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	N. A.	N. A.	4,329.87
16	E.P.S - Basic not annualised for the qtr	1.00	1.03	1.40	2.03	1.57	1.05
	- Annualised	3.99	4.14	5.61	4.06	3.14	1.05

For VENUS REMEDIES LIMITED

 CHAIRMAN & MANAGING DIRECTOR

DIN - 00435503

Notes:

1. The above financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting on November 09, 2016.
2. Statutory auditors have carried out the Limited Review for the said results.
3. The Company caters to only one segment i.e. "Pharmaceutical Formulations"
4. Previous quarter/period's figures have been regrouped/rearranged wherever necessary.

**For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED**



Date: 09.11.2016

Pawan Chaudhary
(Chairman & Managing Director)
DIN: 00435503

Standalone Statement of Assets and Liabilities

Venus Remedies Limited

Particulars	Half Year Ended on	Year Ended on
	30/09/2016	31/03/2016
A EQUITY AND LIABILITIES	(Rs. In Millions)	(Rs. In Millions)
1 Shareholders' funds		
(a) Share capital	114.42	114.42
(b) Reserves and surplus	4353.12	4329.87
Sub-total – Shareholders' funds	4467.54	4444.29
2 Non-current liabilities		
(a) Long-term borrowings	1814.32	1910.26
(b) Deferred tax liabilities (net)	165.87	165.86
(c) Other long-term liabilities	5.91	6.34
(d) Long-term provisions	34.81	37.88
Sub-total – Non-current liabilities	2020.91	2120.34
3 Current liabilities		
(a) Short-term borrowings	1163.64	1150.86
(b) Trade payables	230.55	239.02
(c) Other current liabilities	403.95	366.34
(d) Short-term provisions	5.75	19.68
Sub-total – Current liabilities	1803.89	1775.9
TOTAL – EQUITY AND LIABILITIES	8292.34	8340.53
B ASSETS		
1 Non-current assets		
(a) Fixed assets	5183.94	5138.92
(b) Non-current investments	287.36	287.36
(c) Long-term loans and advances	331.16	328.98
Sub-total – Non-current assets	5802.46	5755.26
2 Current assets		
(a) Current investments		
(b) Inventories	1385.7	1376.93
(c) Trade receivables	579.13	538.85
(d) Cash and cash equivalents	29.59	30.44
(e) Short-term loans and advances	495.46	639.05
Sub-total – Current assets	2489.88	2585.27
TOTAL – ASSETS	8292.34	8340.53

For VENUS REMEDIES LIMITED

[Signature]
CHAIRMAN & MANAGING DIRECTOR



J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1136-37, Sector 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E-mail : jkjcaps@rediffmail.com

REVIEW REPORT

The Board of Directors,
Venus Remedies Limited
51-52, Industrial Area, Phase-I
Panchkula

We have reviewed the accompanying statement of un-audited Financial Results of **Venus Remedies Limited** for the half yearly/Quarter ended 30.09.2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Quarterly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 09.11.2016
Place : Chandigarh

for J. K. Jain & Associates,
Chartered Accountants

J.K. Jain

(J.K. Jain)
Partner

M.No. 083140
FRN. 004025N